CoChat

HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.

Raghav, Kanwal Pratap Singh, Overman, Michael J., Yu, Ruoxi, Meric-Bernstam, Funda, Menter, David, Kee, Bryan K., Muranyi, Andrea, Singh, Shalini, Routbort, Mark, Chen, Ken, Shaw, Kenna Rael, Shanmugam, Kandavel, Maru, Dipen M., Fakih, Marwan, Kopetz, Scott · 2016 · Journal of Clinical Oncology
Cited by 74

The DOI matches its Crossref record.

Abstract

3517 Background: HER2 amplification (HERamp), seen in 5% of KRAS wildtype (WT) metastatic colorectal cancers (mCRC), is associated with resistance to anti-epidermal growth factor receptor antibodies (antiEGFRabs). The purpose of this study was to validate the predictive impact of HERamp in mCRC. Methods: We performed systematic analyses of RAS and BRAF WT mCRC patients (pts) across 2 distinct cohorts. We tested HERamp in cohort 1 (N = 97) using immunohistochemistry and dual in-situ hybridization (HERamp: HER2/CEP17 ≥ 2.2). We validated these findings in cohort 2 (N = 99), which comprised of 37 cases of HERamp mCRC pts identified by next-generation sequencing (HERamp: ≥ 4 copies) and 62 HER2 non-amplified (HER2NA) pts treated previously with antiEGFRabs who served as controls. The primary objective was to compare progression-free survival (PFS) in pts treated with antiEGFRabs. PFS and overall survival (OS) were estimated using Kaplan Meier method and compared using log rank test. Results: HERamp was seen in 14 (14 %) of RAS/BRAF WT pts in cohort 1. In this cohort, median OS (29.1 v 45.1 months (m), P = 0.78) and PFS on first line therapy without an antiEGFRab (PFS1) (9.7 v 8.4 m, P = 0.70) was similar between HERamp and HER2NA pts. A total of 66 pts in cohort 1 received antiEGFRab after first line therapy. Median PFS on antiEGFRab therapy (PFS2) was significantly shorter in pts with HERamp compared to HER2NA tumors (2.9 v 8.1 m, hazard ratio (HR) 5.0, P < 0.0001). These findings were confirmed in cohort 2, in which 69 pts received antiEGFRab after first line therapy and median PFS2 was significantly shorter for HERamp pts compared to HER2NA pts (2.8 v 9.3 m, HR 6.6, P < 0.0001) with a similar OS (P = 0.86) and PFS1 (P = 0.62). Conclusions: HER2 amplification in mCRC is a predictive biomarker for lack of efficacy of antiEGFRab therapy. This magnitude of effect is comparable to RAS mutations; the only other validated predictive biomarker for antiEGFRabs, and affects 1 in 8 patients currently receiving these agents. Patients with RAS/RAF WT mCRC should be screened for HER2 amplification prior to treatment with antiEGFRabs and should be considered for early referral to clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.3517

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 74

Metadata

Authors
Raghav, K. P. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Kee, B. K., Muranyi, A., Singh, S., Routbort, M., Chen, K., Shaw, K. R., Shanmugam, K., Maru, D. M., Fakih, M., & Kopetz, S.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
3517-3517
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2500813010
Cited by
74
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.3517
The paper
Raghav, K. P. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Kee, B. K., Muranyi, A., Singh, S., Routbort, M., Chen, K., Shaw, K. R., Shanmugam, K., Maru, D. M., Fakih, M., & Kopetz, S. (2016). HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.3517

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.